Horizon's Poor Primary Care Performance Overshadows River Vision Buy

Horizon's deal to buy River Vision to bolster its orphan product pipeline is cast into the shade by a disappointing first quarter performance for its primary care business.

Star
Horizon Pharma's orphan drug business is in the ascendant

More from Deals

More from Business